Mauna Kea publishes meta-analysis backing Cellvizio diagnostic accuracy in upper GI cancer

• Mauna Kea Technologies flagged a newly published independent systematic review and meta-analysis supporting its Cellvizio imaging platform in upper GI cancer.
• Results were already presented in the peer-reviewed article, not slated for a future conference readout.
• The review concluded Cellvizio use alongside standard endoscopy improved detection and characterization of suspicious tissue in the esophagus or stomach.
• Findings also indicated fewer biopsies were needed in some settings, supporting a workflow and cost-efficiency rationale for broader clinical use.
• The company positioned the evidence as supportive of reimbursement expansion and adoption in the US, its primary market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mauna Kea Technologies SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260826460836) on August 26, 2026, and is solely responsible for the information contained therein.